Use of a dual monoclonal solid phase and a polyclonal detector to create an immunoassay for the detection of human cardiac Troponin I

被引:17
作者
Oh, SK [1 ]
Foster, K [1 ]
Datta, P [1 ]
Orswell, M [1 ]
Tasaico, K [1 ]
Mai, XL [1 ]
Connolly, P [1 ]
Reamer, R [1 ]
Walsh, R [1 ]
Yang, GH [1 ]
Barlow, E [1 ]
Bluestein, B [1 ]
Parsons, G [1 ]
机构
[1] Bayer Corp, Div Diagnost, E Walpole, MA 02032 USA
关键词
cardaic troponin I; acute myocardial infarction; creatine kinase; NHS activated NSP-acridinium ester; para-magnetic particles; human anti-mouse antibody;
D O I
10.1016/S0009-9120(00)00069-2
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: We report the development of a fully automated, random access, chemiluminescent immunoassay, for the detection of human cardiac Troponin I (cTnI) in serum and plasma for use on the ACS:180(R) System. Design and methods: This assay format uses a combination of two monoclonal antibodies covalently coupled to paramagnetic (PMP) particles as a solid phase and an affinity purified polyclonal antibody, specific to the N-terminal domain of cTnI (peptide-3 region) labeled with a chemiluminescent compound as the detector antibody. The assay offers excellent low-end sensitivity and precision. Results: No interferences are observed from by blood components such as HAMA and drugs used in cardiac therapy. Patient samples tested on the ACS:180 cTnI assay showed good correlation with the Stratus cTnI assay (ACS: cTnI = 1.02*Stratus + 0.05 g/L, r = 0.96, n=1170). Conclusion: Paired with the other ACS:180 cardiac assays, myoglobin and CKMBII, the ACS:180 system now offers an excellent panel of cardiac assay for use in rapid and accurate diagnosis of a myocardial event. Copyright (C) 2000 The Canadian Society of Clinical Chemists.
引用
收藏
页码:255 / 262
页数:8
相关论文
共 22 条
[1]  
ADAMS JE, 1994, CLIN CHEM, V40, P1291
[2]   CARDIAC TROPONIN-I - A MARKER WITH HIGH SPECIFICITY FOR CARDIAC INJURY [J].
ADAMS, JE ;
BODOR, GS ;
DAVILAROMAN, VG ;
DELMEZ, JA ;
APPLE, FS ;
LADENSON, JH ;
JAFFE, AS .
CIRCULATION, 1993, 88 (01) :101-106
[3]   Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes [J].
Antman, EM ;
Tanasijevic, MJ ;
Thompson, B ;
Schactman, M ;
McCabe, CH ;
Cannon, CP ;
Fischer, GA ;
Fung, AY ;
Thompson, C ;
Wybenga, D ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) :1342-1349
[4]   Release kinetics of serum cardiac troponin I in ischemic myocardial injury [J].
Bertinchant, JP ;
Larue, C ;
Pernel, I ;
Ledermann, B ;
FabbroPeray, P ;
Beck, L ;
Calzolari, C ;
Trinquier, S ;
Nigond, J ;
Pau, B .
CLINICAL BIOCHEMISTRY, 1996, 29 (06) :587-594
[5]  
BODOR GS, 1992, CLIN CHEM, V38, P2203
[6]   Evaluation of a new assay for cardiac troponin I vs creatine kinase-MB for the diagnosis of acute myocardial infarction [J].
Brogan, GX ;
Hollander, JE ;
McCuskey, CF ;
Thode, HC ;
Snow, J ;
Sama, A ;
Bock, JL ;
Valentine, M ;
Ward, M ;
Ryan, J .
ACADEMIC EMERGENCY MEDICINE, 1997, 4 (01) :6-12
[7]   CARDIAC SPECIFIC TROPONIN-I RELEASE IN CANINE EXPERIMENTAL MYOCARDIAL-INFARCTION - DEVELOPMENT OF A SENSITIVE ENZYME-LINKED IMMUNOASSAY [J].
CUMMINS, B ;
CUMMINS, P .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1987, 19 (10) :999-1010
[8]   CARDIAC-SPECIFIC TROPONIN-I RADIOIMMUNOASSAY IN THE DIAGNOSIS OF ACUTE MYOCARDIAL-INFARCTION [J].
CUMMINS, B ;
AUCKLAND, ML ;
CUMMINS, P .
AMERICAN HEART JOURNAL, 1987, 113 (06) :1333-1344
[9]  
Datta P, 1999, CLIN CHEM, V45, P2266
[10]  
DUDLEY RF, 1991, J CLIN IMMUNOASSAY, V14, P77